<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228394</url>
  </required_header>
  <id_info>
    <org_study_id>1042-PPD-2002</org_study_id>
    <nct_id>NCT03228394</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Intravenous Ganaxolone in Women With Postpartum Depression</brief_title>
  <official_title>A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the Safety, Pharmacokinetics and Efficacy of IV Administration of
      Ganaxolone in Women with Postpartum Depression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will explore whether ganaxolone is safe and well tolerated in women suffering from
      PPD. In addition, ganaxolone's efficacy in treating depressive symptoms will be assessed
      through a set of exploratory analyses. Plasma levels of ganaxolone will be determined through
      pharmacokinetic analysis. The study results will be used to select a ganaxolone dose and
      dosing regimen for further development in PPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>34 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by the incidence of Treatment-Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Measures</measure>
    <time_frame>11 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by laboratory measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>34 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>34 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by CSSRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>4 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by ECG measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stanford Sleepiness Scale (SSS)</measure>
    <time_frame>4 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by changes in SSS measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>4 days</time_frame>
    <description>Safety and tolerability of IV administered ganaxolone as assessed by changes in physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Plasma Concentration (Cmax) of Ganaxolone</measure>
    <time_frame>34 days</time_frame>
    <description>Analyze the Cmax of IV administered ganaxolone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Steady State (Css) of Ganaxolone</measure>
    <time_frame>34 days</time_frame>
    <description>Analyze the Css of IV administered ganaxolone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve (AUC) of Ganaxolone</measure>
    <time_frame>34 days</time_frame>
    <description>Analyze the AUC of IV administered ganaxolone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD17)</measure>
    <time_frame>34 days</time_frame>
    <description>Efficacy as assessed by HAMD17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Postnatal Depression Scale (EPDS)</measure>
    <time_frame>34 days</time_frame>
    <description>Efficacy as assessed by EPDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spielberger State-Trait Anxiety Inventory six item version (STA6)</measure>
    <time_frame>34 days</time_frame>
    <description>Efficacy as assessed by STA6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>34 days</time_frame>
    <description>Efficacy as assessed by CGI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Depression, Postpartum</condition>
  <condition>Behavioral Symptoms</condition>
  <condition>Mood Disorders</condition>
  <condition>Mental Disorders</condition>
  <condition>Puerperal Disorders</condition>
  <condition>Pregnancy Complications</condition>
  <condition>Postpartum</condition>
  <condition>PPD</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>Ganaxolone IV</description>
    <arm_group_label>Ganaxolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject experienced a Major Depressive Episode, which started between the start of the
             third trimester and 4 weeks following delivery. The Major Depressive Episode must be
             diagnosed according to MINI 7.0 interview

          -  Subject gave birth in the last 6 months

          -  Subject has a HAMD17 score of â‰¥ 26 at screening

          -  Subject must agree to stop breastfeeding from start of study treatment or must agree
             to temporarily cease giving breast milk to her infant(s)

        Exclusion Criteria:

          -  Current or past history of any psychotic illness, including Major Depressive Episode
             with psychotic features

          -  History of suicide attempt within the past 3 years

          -  Active suicidal ideation

          -  History of bipolar I disorder

          -  History of seizure disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with postpartum depression</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolando Gutierrez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum Care</keyword>
  <keyword>Postpartum Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Puerperal Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

